Transgenic mice were generated by injecting the entire rat angiotensinogen gene into the germline of NMRI 
Transgenic mice were generated by injecting the entire rat angiotensinogen gene into the germline of NMRI mice. The resulting transgenic animals were characterized with respect to hemodynamics, parameters of the renin angiotension system, and expression of the transgene. The transgenic line TGM(rAOGEN)123 developed hypertension with a mean arterial blood pressure of 158 mmBHg in males and 132 mmHg in females. In contrast, the transgenic line TGM(rAOGEN)92 was not hypertensive. Rat angiotensinogen was detectable only in plasma of animals of line 123. Total plasma angiotensinogen and plasma angiotensin H concentrations were about three times as high as those of negative control mice. In TGM(rAOGEN)123 the transgene was highly expressed in liver and brain. Transcripts were also detected in heart, kidney and testis. In TGM(rAOGEN)92 the brain was the main expressing organ. In situ hybridization revealed an mRNA distribution in the brain of TGM(rAOGEN)123 similar to the one in rat. In TGM(rAOGEN)92 the expression pattern in the brain was aberrant. These data indicate that overexpression of the angiotensinogen gene in liver and brain leads to the development of hypertension in transgenic mice. The TGM(rAOGEN)123 constitutes a high angiotensin II type
Introduction
The renin angiotensin system (RAS) is the most important regulator of blood pressure and body electrolyte homeostasis. Angiotensinogen (AOGEN), the only high molecular weight protein precursor of angiotensins, is cleaved by renin to angiotensin I (ANG I), which is subsequently converted by the action of converting enzyme to the potent vasoconstrictor octapeptide hormone angiotensin II (ANG II) (for reviews see Peach, 1977; Dzau and Pratt, 1986; Lindpaintner and Ganten, 1991) . The main source of plasma AOGEN is the liver (Campbell et al., 1984) , where its synthesis and release Oxford University Press into the circulation is regulated in response to a number of different stimuli such as steroid hormones (Chang and Perlman, 1987; Feldmer et al., 1991) , cytokines (Brasier et al., 1990 ; Ron et al., 1990a) and ANG II (Klett et al., 1988a,b) . In the past decade the existence of local tissue RAS has been established. Gene expression of components of the RAS, including AOGEN has been demonstrated in a large number of extrahepatic tissues, among them the brain, heart and kidney (Ohkubo et al., 1986; Deschepper et al., 1986; Campbell and Habener, 1987; Dzau et al., 1987; Hellmann et al., 1988; Stornetta et al., 1988) . The transcription of the AOGEN gene in these tissues seems to be regulated in a cell type specific manner (Campbell and Habener, 1986) . In situ hybridization of rat brain revealed a predominant expression of the AOGEN gene within nuclei related to cardiovascular control (Lynch et al., 1986; Bunnemann et al., 1990) . However, the functional relevance of locally generated ANG II in the development of hypertension is not yet fully understood.
An increasing number of studies has successfully employed transgenic animal models to elucidate the participation of candidate genes in the development of pathophysiological changes within the organism (Hsiao et al., 1990; Hammer et al., 1990; Ryan et al., 1990; Weiher et al., 1990) . The generation of hypertensive transgenic rats harbouring the mouse renin gene (Mullins et al., 1990) for the first time provided evidence for a local paracrine mechanism in the development of hypertension. These rats have extremely high blood pressure with low circulating renin and ANG II levels.
To investigate whether the overexpression of the AOGEN gene can also lead to the development of high blood pressure, we generated transgenic mice carrying the rat AOGEN gene. The mouse is particularly suited for these experiments because it is known to have low circulating AOGEN concentrations and because the mouse renin is capable of cleaving rat AOGEN. The use of a heterologous gene (mouse versus rat) allows the differential analysis of the endogenous verus the transgene. We obtained different lines of transgenic mice and report here on the characteristics of these animals with respect to plasma parameters, hemodynamics and the expression pattern of the transgene. We demonstrate that the transgenic mouse line TGM(rAOGEN)123 expresses high levels of the transgene in liver and brain, has elevated plasma AOGEN and ANG II concentrations, and develops hypertension.
Results

Generation of transgenic mice
The genomic rat AOGEN clone pRagl5U (Tanaka et al., 1984) (Figure 1) from tail biopsies (Figure 1) (Figure 2A ). However, as in negative control animals, no specific reaction of the antibody with plasma proteins of TGM(rAOGEN)92 could be detected ( Figure 2A ). This indicates that the concentration of rat AOGEN in the plasma of TGM(rAOGEN)92 is below the limit of detection of the ELISA and that the antibody does not cross-react with the mouse AOGEN.
The total rat and mouse plasma AOGEN concentration was measured by indirect RIA via the generation of ANG I. Animals of TGM(rAOGEN)123 showed >2-fold higher total substrate concentrations than those of TGM(rAOGEN)92 or transgene negative litter-mates ( Figure  2B ). Again there was no difference between male and female animals. Since the data for rat and total AOGEN concentrations were obtained with different (direct and indirect) methods, it is not possible to calculate the exact contribution of rat AOGEN to the concentration of total AOGEN.
Plasma ANG II concentrations were determined by direct radioimmunoassay (RIA) and found to be about three times higher in TGM ( 3). Interestingly, male but not female animals of TGM(rAOGEN)92 also had elevated plasma ANG II concentrations ( Figure 3 ). (Figure 6A and B).
The overall pattern was similar to the expression of the endogenous AOGEN gene in the rat (Bunnemann et al., 1990) . We detected high mRNA levels in the preoptic area (not shown) and in certain nuclei of the hypothalamus, e.g. in the paraventricular hypothalamic nucleus ( Figure 6A,  PHN) , the suprachiasmatic nucleus ( Figure 6A, SC) , the supraoptic nucleus ( Figure 6A, SON) and the arcuate nucleus (not shown). An expression pattern identical to the rat was found also in the locus ceruleus of the pons (not shown), in the Purkinje cell layer of the cerebellar cortex ( Figure  6B , PL) and in the nucleus of the solitary tract ( Figure 6B , NTS) and the inferior olive ( Figure 6B, 10) of the medulla oblongata. There were, however, some differences as compared with the rat. The expression in some nuclei of the thalamus was higher in line 123 animals than in the rat ( Figure 6A, paraventricular thalamic nucleus, PTN) . The substantia nigra also showed high mRNA expression in transgenic animals whereas in the rat this area contains only moderate signals (not shown).
The expression pattern in the brain of animals of line 92 was very much different and comparable with the rat only in pons and medulla ( Figure 6D ). In the other parts of the brain, the very weak expression was restricted to the suprachiasmatic nucleus ( Figure 6C, SC) 
Discussion
The generation of transgenic animals for the investigation of human genetic diseases has gained increasing interest in recent years (Connelly et al., 1989; Hanahan, 1989) . Transgenic animals have found entry also in cardiovascular and hypertension research (Mullins et al., 1989 (Mullins et al., , 1990 Ohkubo et al., 1990; Steinhelper et al., 1990; Field, 1991) . The hypertensive transgenic rats TGR(mREN2)27, carrying the mouse REN 2 gene (Mullins et al., 1990) , were the first monogenic hypertension model and provide direct evidence that not only the classical circulating RAS but also local paracrine tissue RAS can lead to the development of hypertension. Our rationale for introducing the rat AOGEN gene expressed from its own promoter into the genome of the mouse was two-fold. First, mouse renin is capable of cleaving the rat AOGEN (Oliver and Gross, 1966) . With an additional AOGEN gene, we would increase the circulating AOGEN concentration in the mouse, which was reported to be relatively low (Poulsen and Jacobsen, 1986 ). Since plasma substrate concentrations are the rate limiting factor for ANG II formation (Reid et al., 1978) , these animals could provide a model to study RAS kinetics in vivo. Second, using the natural promoter, we wanted to assure a correct tissue specific expression of the transgene, thereby providing a basis for a detailed analysis of cell specific gene expression. Studies with the mouse AOGEN gene (Clouston et al., 1989) and the closely related ail-antitrypsin gene (Shen et al., 1989) indicated that sequences sufficient for a correct expression of the AOGEN gene in transgenic animals reside within 1-2 kb upstream of the start of transcription. Such sequences should therefore be included in the 1.6 kb of 5' flanking sequences present in our transgene. In addition, we (Feldmer et al., 1991) and others (Ron et al., 1990a,b) have shown that promoter elements necessary for glucocorticoid, estrogen and cytokine induction are located within the first 700 bp of the start of transcription.
In TGM(rAOGEN)123 the transgene is expressed in liver and brain as well as in other tissues. In testis and kidney there seems to be a dissociation between the expression of the rat and the endogenous mouse AOGEN genes, the latter being predominantly expressed. In testis, this might reflect species specific differences in the level of expression, since in Sprague -Dawley rats, the mRNA concentration in testis is very low compared with other organs (Hellmann et al., 1988) . This is in contrast to the situation in some mouse strains (Clouston et al., 1989) . Differences between promoter elements mediating testis specific expression of the rat and the mouse genes might be responsible for this phenomenon. Whether the low expression of the transgene in the kidney is due to the lack of kidney specific cis-acting elements on the transgene promoter or whether it is caused by other regulatory mechanisms remains to be investigated. The lack of tissue specific expression in TGM(rAOGEN)92 is likely to be due to integration artifacts (Palmiter and Brinster, 1986) . We can exclude a disruption of the transgene, especially loss of promoter sequences, from Southern analyses using promoter specific probes (data not shown). Position-dependent expression has also been reported for mouse AOGEN minigene constructs in transgenic mice (Clouston et al., 1989) and might be attributed to transcriptional interference from nearby promoters (Proudfoot, 1986) .
The data reported here strongly support the hypothesis that overexpression of AOGEN in a correct tissue specific manner can lead to hypertension. Transgene expression in the liver of TGM(rAOGEN) 123 resulted in increased total plasma AOGEN and ANG II concentrations. The high rat AOGEN mRNA content of the brain was localized by in situ hybridization to areas and nuclei which are similar to the endogenous mRNA distribution in the rat (Bunnemann et al., 1990) . Some of these nuclei are important centres for cardiovascular control and all components of the RAS, 824 a I.
. . _ . . including AOGEN (Imboden et al., 1987) , ANG II immunoreactivity (Lind et al., 1985) and ANG II receptors (Mendelsohn et al., 1984) have been identified within these nuclei. Animals of TGM(rAOGEN) 123 are hypertensive. In contrast, TGM(rAOGEN)92, which, apart from elevated plasma ANG II concentrations in males, did not show any of the characteristic parameters found in TGM(rAOGEN)123, were normotensive. The source of ANG II in line 92 males is unclear at present, since the transgene is only very weakly expressed in the liver and plasma AOGEN concentrations are similar to negative control mice. Plasma ANG II acts directly on vascular smooth muscle cells to increase vascular tone and, in addition, leads to water retention in the kidney by stimulation of aldosterone release from the adrenal gland. Both of these actions increase the blood pressure. Similarly, an overexpression of AOGEN in the brain is likely to result in increased central ANG II concentrations. This leads to an increase in sympathetic nervous system activity via stimulation of noradrenalin release. In addition, modulating regulatory mechanisms in the periphery mediated by central release of humoral factors might be changed by high ANG H concentrations in the brain. Thus, an increased central ANG II concentration can also lead to hypertension. The exact mechanisms underlying a high ANG II mediated hypertension are not known, but the transgenic mice of TGM(rAOGEN)123 provide the opportunity to study these mechanisms and to gain information about the kinetics of the RAS in vivo under conditions of pharmacological intervention or further stimulation of the system. These studies will also help to elucidate the contribution of local tissue RAS to the development of hypertension. The circulating RAS is not the sole determinant of hypertension as suggested by the males of line 92 which are normotensive despite plasma ANG II levels similar to those of line 123 animals. Indirect evidence for the involvement of local tissue RAS is also provided by experiments of Ohkubo et al. (1990) , who have generated transgenic mice with a rat AOGEN gene fused to the mouse metallothionein I (mMT-I) promoter. Although the fusion gene was highly expressed in the liver and the total plasma concentrations of AOGEN and ANG II were similar to the values found in our hypertensive line, these mice were not hypertensive. The mMT-I promoter is predominantly active in the liver but also in the brain (Durham and Palmiter, 1981 (Ohkubo et al., 1983) . It was radiolabelled with [a-32P]dCTP using the random prime method (Feinberg and Vogelstein, 1983) . Hybridization was carried out overnight at 65°C and the membrane was exposed to X-ray film with an intensifying screen at -800C.
Parameters of the RAS Determination of rat AOGEN concentration in plasma was done by ELISA as described (U.Hilgenfeldt, S.Schwind, T.Muley and I.Rubin, submitted), using the monoclonal antibody A1-F6 directed against human AOGEN (Rubin et al., 1988) . Total plasma AOGEN concentration was determined by indirect RIA via the generation of ANG I as described by Schelling et at.
(1980) with slight modifications. Plasma was incubated for a period of 3 h with a 1:10 diluted kidney extract of NMRI mice which served as a source of renin. Three hours were found to be sufficient to cleave quantitatively both rat and mouse AOGEN. Plasma ANG II concentration was measured by RIA essentially as described (Hermann et al., 1988) .
Blood pressure measurements Blood pressure measurements were performed by inserting a PE 10 catheter into the femoral artery of the animals under pentobarbital anesthesia (Jacob et al., 1991) . After the operation (15-25 h) mean arterial blood pressure was recorded on the conscious animals using a Stratham P23 D3 pressure transducer connected to a Gould 2400 recorder. Pressure and heart rate were recorded continously over a period of 15 min. Animals were sacrificed thereafter and organs and blood were taken and processed for further experiments.
RNA analysis A 290 bp PvuII-BamHI fragment of pRagl6 was cloned into the BamHI and SmaI restriction sites of the transcription vector pGEM 4 (Promega Biotech). The resulting plasmid pRagO.3G4 was linearized with EcoRl and then used for cRNA synthesis utilizing T7 RNA polymerase according to the method of Melton et al. (1984) .
The mouse AOGEN probe pMagO.15G4z which allowed for cRNA synthesis with T7 RNA polymerase after linearizing with EcoRI was constructed in the following way. A 6.3 kb BamHI fragment from the genomic mouse AOGEN clone mAO (R.Metzger, unpublished) was subcloned into Bluescript SK II (Stratagene) and subsequently digested with EcoRI and BglII. The resulting 158 bp fragment was isolated and cloned into the EcoRI and BamHI sites of pGEM4z (Promega Biotech) to yield the plasmid pMagO.15G4z.
RNase protection assays were performed essentially as described by Mullins et al. (1990) . Briefly, total RNA was extracted from different tissues using the LiCl/urea method (Auffray and Rougeon, 1980) . Hybridization was carried out overnight with 2 x 105 c.p.m. each of freshly labelled antisense probes at 65 'C. RNase resistant hybrids were separated on a 5% sequencing gel, which was then exposed to X-ray film at -80°C.
In situ hybridization In situ hybridization on mouse brain was performned as previously described (Bunnemann et al., 1990) 
